The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
.
Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma
Advising the management and majority physician owners of GI Alliance, the largest gastroenterology practice in the United States, on its recapitalization and buyout of minority partner, Waud Capital
Advised Airtower Networks on its strategic growth capital raise from DIF Capital Partners
Advised Fusion Connect, Inc., a leading service provider of cloud communications and secure network solutions with a focus on serving mid-market and enterprise businesses on its comprehensive balance sheet recapitalization
Advised the Ad Hoc Group of First Lien Lenders on the Chapter 11 restructuring of Speedcast International Limited (ASX:SDA)
Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share
Advising US Acute Care Solutions, the largest majority physician-owned emergency medicine practice in the United States, on its recapitalization and buyout of minority partner, Welsh Carson
Advised the Company on its CCAA and Ch.15 proceedings and $1.5bn sale through a Sale and Investment Solicitation Process (SISP)
Advised the ad-hoc Cross-Holder Group of lenders on the fully consensual Prepackaged Plan of Reorganization of iQor Holdings Inc., a business process outsourcing company
Advised Gannett Co., Inc., a news media and marketing solutions company, on the refinancing of ~$500mm of its term loan with convertible notes
Advised Ad Hoc Group of First Lien Term Loan Lenders on Akorn’s in-court recapitalization
Advised the Ad Hoc Group of First Lien Lenders on the Chapter 11 restructuring of Skillsoft Limited, a leading provider of e-learning and performance support solutions globally
Advised Ad Hoc Group of First Lien Term Loan B Lenders on the restructuring of 4L Holdings Corporation
Advised the Ad Hoc Group of 1L lenders with respect to Fusion's Chapter 11 proceeding
Advised F+W Media, a content and e-commerce company focused on a variety of special interest categories, on the sale of its book publishing business as part of its broader in-court restructuring
Advised Gannett Co., Inc., a media and marketing solutions company, in relation to an unsolicited acquisition proposal from and successful proxy contest with MNG Enterprises, Inc.
Advised Wave Computing, a leading artificial intelligence solutions company developing proprietary dataflow-based architecture systems, on its successful $86mm Series E financing
Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt
Advised The Bank of New York Mellon in its role as the Indenture Trustee to selected First Lien Notes throughout Avaya’s Chapter 11 proceedings
Advised F+W Media, a content and e-commerce company focused on a variety of special interest categories, on the out-of-court restructuring of its c.$100 million term loan and a $15 million new money investment from existing lenders
Advised the Ad Hoc Group of Senior Secured Noteholders in connection with the restructuring of Goodman Networks.
Advised the Special Committee of the Board of Directors of IAC/InterActiveCorp, a leading media and internet company, on the potential creation of a new class of non-voting common stock
Advised the Special Committee of the Board of Directors of Concordia International, a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, on its strategic review process
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
Advised Rofin-Sinar Technologies, Inc., a leading manufacturer of industrial laser sources and laser-based solutions and components, on its sale to Coherent, Inc., a leading provider of lasers and laser-based technology for scientific, commercial and industrial customers